The stream · Daily digest
The stream: Sunday, November 8, 2026
1 brief, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 1
-
Johnson & Johnson reports 73% PSA response rate in Phase 1 study
Johnson & Johnson said that 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in PSA, and 47 percent (7 of 15 patients) achieved reductions of at least 90 percent. The company noted no Grade 3 or higher treatment-related adverse events in this early analysis.
Source: Company press release (PR Newswire), November 8, 2026